GlassScriptPhysician profile
Harry Menon
NPI 1265826390
$99,532.97
in general payments reported to CMS, 2019-2025
44 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.99 · 2022: $197 · 2023: $15K · 2024: $35K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $31K · Travel and Lodging: $6,460 · Food and Beverage: $5,960 · Honoraria: $1,665 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,259.00 |
| Consulting Fee | $30,643.90 |
| Travel and Lodging | $6,459.59 |
| Food and Beverage | $5,960.14 |
| Honoraria | $1,665.00 |
| Education | $335.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52,597.39 | 2023-2025 | Imfinzi, Enhertu, Lynparza |
| Genzyme Corporation | $15,600.71 | 2023-2025 | |
| Genentech USA, INC. | $13,470.46 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Merck Sharp & Dohme LLC | $5,611.50 | 2023-2024 | Keytruda |
| Pfizer INC. | $3,414.77 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $2,869.65 | 2024-2025 | Vimseltinib, Qinlock, Romvimza |
| Incyte Corporation | $2,045.97 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $899.67 | 2024-2025 | Vanflyta, Enhertu, Datroway |
| Astellas Pharma US INC | $382.64 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Janssen Biotech, INC. | $334.72 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Adaptive Biotechnologies Corporation | $287.00 | 2024-2025 | Clonoseq |
| Sobi, INC | $284.76 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $181.96 | 2024-2025 | Libtayo |
| Caris Mpi, INC. | $139.34 | 2025 | Mi Cancer Seek |
| Seagen INC. | $129.17 | 2023-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $113.82 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $112.22 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Mirati Therapeutics, INC. | $108.94 | 2023 | Krazati |
| Genentech, INC. | $99.22 | 2022 | |
| Eisai INC. | $86.75 | 2021-2025 | |
| Springworks Therapeutics, INC. | $71.94 | 2024-2025 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $64.61 | 2022 | |
| Astellas Pharma Global Development | $56.39 | 2025 | Padcev |
| Abbvie INC. | $52.89 | 2024-2025 | |
| Celgene Corporation | $48.53 | 2023 | Pomalyst |
| Ipsen Biopharmaceuticals, INC | $47.06 | 2024-2025 | Onivyde |
| Lilly USA, LLC | $46.25 | 2024-2025 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $42.76 | 2025 | |
| Karyopharm Therapeutics INC. | $33.93 | 2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $32.78 | 2022 | |
| Exelixis INC. | $30.54 | 2025 | Cabometyx |
| Spectrum Pharmaceuticals INC. | $27.95 | 2023 | Rolvedon |
| Kite Pharma, INC. | $26.68 | 2025 | Yescarta |
| Novartis Pharmaceuticals Corporation | $26.32 | 2025 | |
| Puma Biotechnology, INC. | $26.19 | 2025 | |
| Genmab U.S., INC. | $25.27 | 2025 | Epkinly |
| Legend Biotech USA INC. | $23.27 | 2025 | Carvykti |
| Beigene USA, INC. | $19.31 | 2023 | Brukinsa |
| Aimmune Therapeutics, INC. | $18.72 | 2025 | Zenpep |
| Beone Medicines USA, INC. | $18.70 | 2025 | Brukinsa |
| Novocure INC. | $13.92 | 2025 | Optune Lua (Novottf-200t) |
| Janssen Scientific Affairs, LLC | $8.30 | 2025 | Talvey, Tecvayli, Carvykti |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.